

Provided by:



Hematology Case Conference 2023-2024 2023

Hematology Case Conference 2023-2024 - 6/16/2023

June 16, 2023

8:00 AM - 9:00 AM

12-122 Conference Room, Perelman Center South Pavilion/virtual MS teams

Target Audience

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss and identify the proper diagnosis for various hematologic diseases, based on the knowledge of the molecular
- 2 Describe how to prepare a proper, evidence-based treatment plan for hematologic diseases based on best practice
- 3 Discuss how to effectively communicate the treatment plan effectively to the consultant team

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC: up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses: This activity is for 1.00 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

For more information, please contact
Alexa Davis
(215) 662-3681
alexa.davis@uphs.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Acknowledgement of Commercial Support*

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual | Individual's role in activity | Name of Ineligible Company(s) / Nature of Relationship(s) |
|---------------------------|--|---|
| Adam Cuker, MD | Co-Director | Nothing to disclose - 10/19/2022 |
| Charles S. Abrams, MD | Course Director | Nothing to disclose - 10/24/2022 |
| Sriram Anbil, MD | Faculty, Other Planning Committee Member | Nothing to disclose - 07/19/2022 |
| Tara Azizi, MSN | Nurse Planner | Nothing to disclose - 11/09/2022 |
| Erin Aakhus, MD | Other Planning Committee Member | Nothing to disclose - 09/07/2022 |
| Rahul S Bhansali, MD | Other Planning Committee Member | Nothing to disclose - 04/26/2023 |
| Lawrence F Brass, MD, PhD | Other Planning Committee Member | Nothing to disclose - 10/22/2022 |
| Timothy J Brown, MD | Other Planning Committee Member | Nothing to disclose - 10/19/2022 |
| David Cantor, MD, PhD | Other Planning Committee Member | Nothing to disclose - 04/26/2023 |
| Elaine Chiang, MD | Other Planning Committee Member | Stocks or stock options, excluding diversified mutual funds-Pfizer, Inc. - 10/25/2022 |
| Bryan T Ciccarelli, MA | Other Planning Committee Member | Nothing to disclose - 02/06/2023 |
| Matthew Connor, MD | Other Planning Committee Member | Nothing to disclose - 05/15/2023 |

| | | |
|----------------------------|---------------------------------|--|
| Mia Djulbegovic, MD | Other Planning Committee Member | Nothing to disclose - 07/13/2022 |
| Putzer Hung, MD, PhD | Other Planning Committee Member | Nothing to disclose - 07/22/2022 |
| Peter Klein, MD, PhD | Other Planning Committee Member | Nothing to disclose - 09/30/2022 |
| Benjamin Manning, MD, PhD | Other Planning Committee Member | Nothing to disclose - 09/09/2022 |
| Ariela L Marshall, MD | Other Planning Committee Member | Nothing to disclose - 01/10/2023 |
| Vikram Paralkar, MD | Other Planning Committee Member | Nothing to disclose - 09/07/2022 |
| Scott A Peslak, MD, PhD | Other Planning Committee Member | Consulting Fee-Fulcrum Therapeutics (Relationship has ended) - 09/07/2022 |
| Allyson Pishko, MD | Other Planning Committee Member | Grant or research support-Sanofi Genzyme (Relationship has ended) Advisor-Biomarin - 10/24/2022 |
| Jacob B Reibel, MD | Other Planning Committee Member | Nothing to disclose - 09/08/2022 |
| James E Russell, MD | Other Planning Committee Member | Consulting Fee-Sanofi Genzyme (Relationship has ended) Consulting Fee-American Regent, Inc. (Relationship has ended) - 11/01/2022 |
| Farzana Sayani, MD | Other Planning Committee Member | Grant or research support-Novartis (Advanced Health Media) (Relationship has ended) Grant or research support-Celgene Corporation (Relationship has ended) Grant or research support-Agios Pharmaceuticals Grant or research support-Imara (Relationship has ended) Grant or research support-Aruvant Sciences (Relationship has ended) Grant or research support-Protagonist Therapeutics (Relationship has ended) - 05/11/2023 |
| Eleanor Taranto, MD | Other Planning Committee Member | Nothing to disclose - 07/11/2022 |
| Minh Than, MD, PhD | Other Planning Committee Member | Nothing to disclose - 07/18/2022 |
| Elizabeth Traxler, MD, PhD | Other Planning Committee Member | Nothing to disclose - 10/25/2022 |
| Shannon Ugarte, MD | Other Planning Committee Member | Nothing to disclose - 07/07/2022 |

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of

the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.